BioNTech SE Sponsored ADR $BNTX Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lessened its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 73.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,619 shares of the company's stock after selling 56,916 shares during the quarter. Robeco Institutional Asset Management B.V.'s holdings in BioNTech were worth $2,195,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Banque Cantonale Vaudoise purchased a new stake in shares of BioNTech during the first quarter worth approximately $36,000. Banque Transatlantique SA purchased a new stake in shares of BioNTech during the first quarter worth approximately $80,000. Costello Asset Management INC purchased a new stake in shares of BioNTech during the first quarter worth approximately $91,000. Goodman Advisory Group LLC purchased a new stake in shares of BioNTech during the first quarter worth approximately $105,000. Finally, NewEdge Advisors LLC purchased a new stake in shares of BioNTech during the first quarter worth approximately $167,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Morgan Stanley upped their price objective on BioNTech from $132.00 to $133.00 and gave the stock an "overweight" rating in a report on Thursday, July 10th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of BioNTech in a report on Saturday, September 27th. HC Wainwright reaffirmed a "buy" rating and set a $136.00 price objective on shares of BioNTech in a report on Monday, September 8th. JPMorgan Chase & Co. upped their price objective on BioNTech from $116.00 to $121.00 and gave the stock a "neutral" rating in a report on Monday, September 22nd. Finally, Wells Fargo & Company set a $150.00 price objective on BioNTech and gave the stock an "overweight" rating in a report on Tuesday, August 5th. Ten research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $134.46.

BioNTech Stock Up 0.9%

BNTX opened at $106.06 on Wednesday. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. The firm has a market cap of $25.50 billion, a P/E ratio of -66.29 and a beta of 1.45. BioNTech SE Sponsored ADR has a 52 week low of $81.20 and a 52 week high of $129.27. The business's fifty day simple moving average is $104.72 and its 200 day simple moving average is $103.44.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The business had revenue of $306.46 million for the quarter, compared to analysts' expectations of $161.26 million. During the same quarter last year, the company posted ($3.36) earnings per share. The business's quarterly revenue was up 102.6% compared to the same quarter last year. BioNTech has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 EPS for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.